2 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Acute Bilineal Leukemia: new trials by email Literature Review of Acute Bilineal Leukemia trials Research Report on Acute Bilineal Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Azacitidine, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2020-05-05 | 2026-10-05 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2018-09-18 | 2026-09-14 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Ipilimumab, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 150 | 2015-04-07 | 2025-06-08 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Clofarabine, Cytarabine, Dexamethasone - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2014-10-27 | 2024-03-22 |
Leukemia, Biphenotypic, Acute (5) · Leukemia, Myeloid, Acute (4) · Leukemia, Myelomonocytic, Chronic (3) · Myelodysplastic Syndromes (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Leukemia, Myeloid (4) · Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Pathologic Processes (3)
Azacitidine (3) · venetoclax (2) · 2-Propanol (1) · AP 1903 reagent (1) · CT-P10 (1) · CTLA-4 Antigen (1) · Calcium Dobesilate (1) · Clofarabine (1) · Cytarabine (1) · Dexamethasone (1) · Idarubicin (1) · Ipilimumab (1) · Nivolumab (1) · Rituximab (1) · Sorafenib (1)
M.D. Anderson Cancer Center (4) · Fred Hutchinson Cancer Center (1)
United States (5)
Betul Oran (1) · Courtney DiNardo (1) · Elias Jabbour (1) · Elizabeth Krakow (1) · Naval Daver (1)
PMID 34980577, PMID 35078972, PMID 38391202
P30CA015704 (1)